1 Stock Under $50 with Exciting Potential and 2 Facing Challenges

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

KRUS Cover Image

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here is one stock under $50 with huge potential and two that may have trouble.

Two Stocks Under $50 to Sell:

Kura Sushi (KRUS)

Share Price: $45.20

Known for its conveyor belt that transports dishes to diners, Kura Sushi (NASDAQ:KRUS) is a chain of sushi restaurants serving traditional Japanese fare with a touch of modernity and technology.

Why Are We Hesitant About KRUS?

  1. Disappointing same-store sales over the past two years show customers aren’t responding well to its menu offerings and dining experience
  2. Cash burn makes us question whether it can achieve sustainable long-term growth
  3. Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution

At $45.20 per share, Kura Sushi trades at 25.8x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including KRUS in your portfolio.

QuidelOrtho (QDEL)

Share Price: $14.34

Born from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (NASDAQ:QDEL) develops and manufactures diagnostic testing solutions for healthcare providers, from rapid point-of-care tests to complex laboratory instruments and systems.

Why Is QDEL Risky?

  1. Weak constant currency growth over the past two years indicates challenges in maintaining its market share
  2. 23 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
  3. Diminishing returns on capital suggest its earlier profit pools are drying up

QuidelOrtho’s stock price of $14.34 implies a valuation ratio of 7.4x forward P/E. Check out our free in-depth research report to learn more about why QDEL doesn’t pass our bar.

One Stock Under $50 to Watch:

Patterson-UTI (PTEN)

Share Price: $11.66

Operating 135 Tier-1 super-spec rigs that can handle the industry's most demanding drilling projects, Patterson-UTI (NASDAQ:PTEN) provides contract drilling rigs, hydraulic fracturing, and drill bits to oil and gas operators.

Why Are We Fans of PTEN?

  1. Annual revenue growth of 12.5% over the last ten years was superb and indicates its market share increased during this cycle
  2. Economies of scale give it more fixed cost leverage than its smaller competitors
  3. EBITDA margin improvement of 3.4 percentage points over the last five years demonstrates its ability to scale efficiently

Patterson-UTI is trading at $11.66 per share, or 6.1x forward EV-to-EBITDA. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article